

***Decision Point: GF/B39/EDP15: Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period***

The Board:

1. *Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SCo4/DPo2;*
2. *Approves the additional incremental funding recommended for certain UQD of the following country disease components: (i) Burundi Malaria, and (ii) Philippines TB, as listed in Table 2 of GF/B39/ER12, based on available funding approved by the Audit and Finance Committee;*
3. *Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and*
4. *Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.*

***This decision does not have material budgetary implications for operating expenses***

**Table 2: Secretariat’s Funding Recommendation on Funding Unfunded Quality Demand from 2017-2019 Allocation Period**  
*Please note that each country name is linked to the extranet site where supporting documents are available for review*

<b>N</b>	<b>Applicant</b>	<b>Disease Component</b>	<b>Grant Name</b>	<b>Additional Funding Source</b>	<b>Currency</b>	<b>Previously Approved Program Budget</b>	<b>Recommended Additional Funding</b>	<b>Revised Program Budget</b>	<b>Strategic Priority Areas For Investments</b>
1	Burundi	Malaria	BDI-M-UNDP	Portfolio Optimization	USD	36,656,018	4,870,607	41,526,625	Continuation of IRS activities in the four districts previously supported by the Global Fund
2	Philippines	Tuberculosis	PHL-T-PBSP	Portfolio Optimization	USD	88,543,887	10,000,000	98,543,887	US\$7,000,000 for Multi Drug Resistant TB interventions US\$3,000,000 for financing Drug Susceptible TB interventions

**Table 2: Extensions Approved by the Secretariat**

<b>Applicant</b>	<b>Disease Component</b>	<b>Grant Name</b>	<b>Currency</b>	<b>Total Extension Budget</b>	<b>Additional Funding</b>	<b>Proposed Extension Duration (Months)</b>	<b>Proposed End Date</b>
Elimination 8	Malaria	QPA-M-E8S	USD	2,093,927	2,093,927	6	31/03/2019